Tonix is a clinical-stage biopharmaceutical company with a portfolio composed of CNS, rare disease, immunology and infectious disease product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Our lead CNS candidate is in mid-Phase 3 development for the management of fibromyalgia with interim data expected in 2Q'23. We also expect to initiate three Ph 2 studies in 1Q'23. Our Immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer. Lastly, Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox, next-generation vaccines to prevent COVID-19, and a platform to make fully human monoclonal antibodies to treat COVID-19.
Ticker:
TNXP
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Multiple Therapeutics
Lead Product in Development:
TNX-102 SL
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
